$10 Million Gift to Open the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai
Mount Sinai received a second $10 million gift from the Waldman Family. This gift will open the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai.
Housed within the Kimberly and Eric J. Waldman Department of Dermatology at the May Center for Mount Sinai Doctors, at 5 E. 98th Street in Manhattan, the new Waldman Melanoma and Skin Cancer Center will provide patients with comprehensive, coordinated services across the Mount Sinai Health System, in partnership with the Tisch Cancer Institute at Mount Sinai.
With both doctors and scientists working together, exchanging clinical insights and laboratory findings, the goal of the Waldman Melanoma and Skin Cancer Center is to design the best treatment for each patient—and to advance early melanoma and skin cancer diagnosis, treatment, and research. With approximately 75,000 new cases of melanoma diagnosed in the United States each year and 9,000 melanoma-related deaths, melanoma is the most dangerous skin cancer.
“The Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center will capitalize on the benefits of Mount Sinai’s expertise in translational research and provide patients with early detection and prevention, new therapies and outside the box research approaches at one of the most advanced centers in the country," says Emma Guttman-Yassky, Waldman Professor and Chairwoman, The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai. "I am honored the Waldman Family is sharing their generous support for this new state-of-the art center that will help position Mount Sinai as a leader in this field.”
“We are proud to support this new and innovative initiative,” said Mr. Waldman. “We look forward to the advancement of scientific discoveries in melanoma, help patients receive the best care possible for this disease and potentially save thousands of lives.”
With highly trained specialists skilled in caring for different types of melanoma, patients at the Waldman Melanoma and Skin Cancer Center will have access to the newest diagnostics and therapies such as Canfield Vectra180 – a 3D whole body imaging system that captures nearly the entire skin surface in macro quality resolution, and will be able to capture early skin cancer lesions; Nevisense—a safe diagnostic support tool utilizing Electrical Impedence Spectroscopy (EIS) which is applied as a harmless electrical signal to the skin; Vivascope 1500—a non-invasive confocal imaging system which offers a non-invasive way to image the skin to the superficial collagen layers; and innovative technologies which non-invasively collects skin cells through adhesive patches rather than a scalpel to diagnose atypical pigmented lesions (or moles) at high risk for melanoma.
“Melanoma can be a deadly skin cancer and a small tumor on the skin can metastasize quickly if not treated,” explains Jonathan Unger, MD, Medical Director, Waldman Melanoma and Skin Cancer Center and Assistant Professor of Dermatology, Icahn School of Medicine at Mount Sinai. “But at the Center, our job is to diagnose patients with melanoma as well as other skin cancer early, treat the cancer as soon as we find it and prevent it from spreading.” Mount Sinai’s Department of Dermatology carries out over 50,000 skin cancer checks per year throughout the Mount Sinai Health System.
Additionally, Mount Sinai’s Department of Dermatology is one of very few clinical sites in the world to offer two non-invasive imaging devices that can evaluate, diagnose and monitor skin cancers. Optical coherence tomography (OCT) and reflectance confocal microscopy (RCM) are two technologies that can be used to view cellular structures below the surface of the skin, enhancing diagnostic accuracy of both benign and skin cancer lesions. These devices are non-invasive and have been shown to reduce the need for biopsy. They are also useful in delineation of surgical margins as well as for long-term monitoring over time.
Said Dr. Ungar, “This new facility allows our talented Mount Sinai faculty the ability to provide the highest quality care to our patients with an integrated approach that combines early detection and treatment with advanced surgical and Mohs techniques to remove skin cancers, as well as additional services as needed from oncologists and other specialties, while providing patients with the best possible results all in one place.”
The Center's leadership team includes Dr. Emma Guttman-Yassky, as well as a team of reputable experts including dermatologists, surgeons, fellows, nurses and clinicians specializing in the fields of dermatology, pathology and oncology offering patients specialized care in prevention, diagnosis and treatment of melanoma. Additionally, all patients are assigned a patient navigator to help assist with scheduling appointments, receive medications and specific treatments and administrative supportive care. For more information about the Center click here.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.